The Creoptix™ WAVEsystem provides a reliable environment for fragment-based drug discovery (FBDD) and small molecule screening, allowing for accurate off-rate kinetic analysis of crude reaction mixtures. With exquisite sensitivity, the ability to resolve extremely rapid dissociating kinetics, and innate compatibility with the high molecular weight ratios characteristic of most drug discovery programs, the Creoptix™ WAVEsystem improves fragment-based screening and kinetic analysis of small molecules to accelerate drug development.